These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 27939801

  • 41. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women.
    Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, Eriksen EF, Miller PD.
    Kidney Int; 2008 Sep; 74(5):641-8. PubMed ID: 18509324
    [Abstract] [Full Text] [Related]

  • 42. Concurrence of rheumatoid arthritis and calcium pyrophosphate deposition disease: A case collection and review of the literature.
    Sabchyshyn V, Konon I, Ryan LM, Rosenthal AK.
    Semin Arthritis Rheum; 2018 Aug; 48(1):9-11. PubMed ID: 29338885
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial.
    N Engl J Med; 2007 May 03; 356(18):1809-22. PubMed ID: 17476007
    [Abstract] [Full Text] [Related]

  • 45. Fracture risk and zoledronic acid therapy in men with osteoporosis.
    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E.
    N Engl J Med; 2012 Nov 01; 367(18):1714-23. PubMed ID: 23113482
    [Abstract] [Full Text] [Related]

  • 46. Giant cell arteritis with visual loss following zoledronic acid infusion.
    Metyas S, Ibrahim M, Solyman J, Yeter KC, Arkfeld DG.
    Int J Rheum Dis; 2014 Jan 01; 17(1):113-5. PubMed ID: 24472274
    [Abstract] [Full Text] [Related]

  • 47. Zoledronic acid treatment of osteoporosis: effects in men.
    Johnson DA, Williams MI, Petkov VI, Adler RA.
    Endocr Pract; 2010 Jan 01; 16(6):960-7. PubMed ID: 20497935
    [Abstract] [Full Text] [Related]

  • 48. Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
    Billington EO, Horne A, Gamble GD, Maslowski K, House M, Reid IR.
    Osteoporos Int; 2017 Jun 01; 28(6):1867-1874. PubMed ID: 28233020
    [Abstract] [Full Text] [Related]

  • 49. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.
    Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD.
    Am J Ther; 2011 Sep 01; 18(5):375-81. PubMed ID: 20460985
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Effects of zoledronic acid on osteoporosis patients in Japan.].
    Tanaka S.
    Clin Calcium; 2017 Sep 01; 27(2):257-261. PubMed ID: 28123128
    [Abstract] [Full Text] [Related]

  • 52. Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis.
    Tasci I, Safer U, Cintosun U, Bozoglu E, Naharci I, Aydogdu A, Meric C, Doruk H.
    Endocr Metab Immune Disord Drug Targets; 2016 Sep 01; 16(1):32-8. PubMed ID: 26530338
    [Abstract] [Full Text] [Related]

  • 53. Calcium pyrophosphate and pseudogout.
    Zarins B, McInerney VK.
    Arthroscopy; 1985 Sep 01; 1(1):8-16. PubMed ID: 3004529
    [Abstract] [Full Text] [Related]

  • 54. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
    Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM.
    Osteoporos Int; 2014 Apr 01; 25(4):1225-35. PubMed ID: 24287510
    [Abstract] [Full Text] [Related]

  • 55. Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget's disease.
    Watts MR, Ellims AH, Eccleston DS.
    Med J Aust; 2014 Feb 17; 200(3):150. PubMed ID: 24528425
    [No Abstract] [Full Text] [Related]

  • 56. Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases.
    Lee JJ, Cheng SJ, Wang YP, Jeng JH, Chiang CP, Kok SH.
    Head Neck; 2013 Jan 17; 35(1):E6-10. PubMed ID: 21523843
    [Abstract] [Full Text] [Related]

  • 57. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M.
    Curr Med Res Opin; 2007 Jul 17; 23(7):1575-82. PubMed ID: 17559749
    [Abstract] [Full Text] [Related]

  • 58. Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration.
    Didden K, De Smet L, Vandenberghe L, Sciot R, Degreef I.
    Chir Main; 2012 Dec 17; 31(6):355-7. PubMed ID: 23177907
    [Abstract] [Full Text] [Related]

  • 59. Drug-induced dermatomyositis after zoledronic acid.
    Tong PL, Yu LL, Chan JJ.
    Australas J Dermatol; 2012 Nov 17; 53(4):e73-5. PubMed ID: 23157790
    [Abstract] [Full Text] [Related]

  • 60. Pharmacist-run zoledronic acid clinic.
    Traina AN, Kane MP, Bakst G, Abelseth JM, Busch RS.
    Am J Health Syst Pharm; 2011 Aug 01; 68(15):1399-403. PubMed ID: 21785027
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.